Biotech Values

[mcbio]

RCPT

The name of the game is more selective S1PR agonists with improved safety profile compared to the 1st gen - Gilenya and I think so far they are all hitting bumps and the S1P system is not sufficiently understood.

Thanks very much for the detailed response. Is RCPT's drug primarily just limited to potentially improving upon the safety of Gilenya or is there the potential for it to improve upon efficacy as well? Ideally, I'd hope there be potential for improvements in both.